REUTERS: Exact Sciences Corp said on Monday it will buy peer Genomic Health Inc for about US$2.8 billion in cash and stock, expanding the cancer diagnostic company's testing capabilities to breast and prostate cancers.
Shares of Genomic Health rose 2.7per cent to US$70.51 in early trading, while Exact Sciences' shares fell 12.1per cent to US$103.6. Colorectal cancer testing represents a US$15 billion opportunity in the U.S., according to Exact Sciences.
Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más: